Watch for the formal Schedule TO filing with the offer price and conditions; the stock will trade on the expected deal spread until close. Monitor regulatory clearance and any competing bids.
Price Chart
Executive Summary
Viatris Inc. announced an agreement to acquire Pacira BioSciences through a tender offer by its wholly owned subsidiary, Peach Purchaser Sub Inc., for all outstanding shares of Pacira common stock. The transaction positions Viatris as a leader in non-opioid pain management therapies, adding two established medicines and commercial, market access, medical affairs, and R&D capabilities. The tender offer has not yet commenced, and the per-share price and total deal value are not disclosed in this preliminary communication.
Key Financial Metrics
Key Facts
- Viatris agreed to acquire Pacira BioSciences via a tender offer for all outstanding shares, announced on October 8, 2026.
- The transaction adds two established non-opioid pain medicines and complementary capabilities to Viatris.
- Pacira's medicines are described as 'high-margin U.S. medicines that are expected to be immediately accretive' to Viatris.
- The tender offer has not yet commenced; a Schedule TO and Schedule 14D-9 will be filed with the SEC.
- The acquisition is subject to conditions including a majority of Pacira shares being tendered and regulatory approvals.
Financial Impact
Deal value and per-share price not disclosed in this filing; Pacira's established non-opioid pain portfolio expected to be immediately accretive to Viatris.
Risk Factors
- Failure to obtain required regulatory approvals or satisfy tender conditions could scuttle the deal.
- A competing offer could emerge, potentially raising the acquisition price or derailing the transaction.
- Integration risks: Viatris may not achieve expected synergies or operating efficiencies.
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| SC TO-C Filing (Primary) | 0001140361-26-039148 |
| Document: ef20083527_ex99-1.htm | 0001140361-26-039148 |
| Document: 0001140361-26-039148-index-headers.html | 0001140361-26-039148 |
| Document: 0001140361-26-039148-index.html | 0001140361-26-039148 |
| Document: 0001140361-26-039148.txt | 0001140361-26-039148 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 13, 2026 15d ago | SC 13D/A | $36.40 | awaiting T+20 | awaiting T+20 | $36.38 (+0.05%) |
Oct 8, 2026 20d ago | SC TO-C | $36.31 | awaiting T+20 | awaiting T+20 | $36.38 (+0.19%) |
Oct 8, 2026 21d ago | 144 | $36.39 | awaiting T+20 | awaiting T+20 | $36.38 (−0.03%) |
Oct 8, 2026 21d ago | 8-K | $36.39 | awaiting T+20 | awaiting T+20 | $36.38 (−0.03%) |
Oct 8, 2026 21d ago | SC TO-C | $36.39 | awaiting T+20 | awaiting T+20 | $36.38 (−0.03%) |
Aug 6, 2026 12w ago | Press Release | $25.58 $26.60 | ▲ +3.99% | ▲ +3.39% | $36.38 (+42.22%) |
Jul 22, 2026 14w ago | Press Release | $25.59 $24.36 | ▼ −4.81% | ▼ −7.70% | $36.38 (+42.16%) |
Jun 30, 2026 17w ago | 8-K | $25.37 $26.47 | ▲ +4.34% | ▲ +5.36% | $36.38 (+43.40%) |
Jun 12, 2026 19w ago | Insider Cluster | $22.74 $25.54 | ▲ +12.31% | ▲ +13.06% | $36.38 (+59.98%) |
Jun 4, 2026 20w ago | DEFA14A | $22.75 $25.59 | ▲ +12.48% | ▲ +10.62% | $36.38 (+59.91%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers